WEKO3
アイテム
{"_buckets": {"deposit": "a476de4c-a6ac-4be6-8998-e5a33ea1302f"}, "_deposit": {"created_by": 4, "id": "692", "owners": [4], "pid": {"revision_id": 0, "type": "depid", "value": "692"}, "status": "published"}, "_oai": {"id": "oai:uoeh-u.repo.nii.ac.jp:00000692", "sets": ["28"]}, "author_link": ["1861", "1853", "1863", "1865", "1859", "1860", "1862", "1854", "1858", "1855", "1864", "1857", "1856", "1852"], "item_10001_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-06-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "110", "bibliographicPageStart": "103", "bibliographicVolumeNumber": "37", "bibliographic_titles": [{"bibliographic_title": "産業医科大学雑誌"}, {"bibliographic_title": "Journal of UOEH", "bibliographic_titleLang": "en"}]}]}, "item_10001_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The rate of recurrence of subacute thyroiditis (SAT) during prednisolone (PSL) therapy is approximately 10 to 20%. However, there is little or no information on the time period to relapse following administration of a tapered dose of PSL and the factors associated with such relapse. The aim of this study was to determine the correlation between SAT recurrence and PSL tapering regimen used in the treatment of SAT. This study was a medical record-based retrospective study and involved 26 patients (3 men, 23 women) who received PSL therapy for SAT. The primary endpoint was the association between recurrence and number of days required to taper daily PSL dose to 5 mg. The secondary endpoint was the relationship between recurrence and several variables including age, clinical score, free thyroxine, inflammatory reaction, thyroglobulin, total treatment time, total dose of PSL and presence or absence of creeping thyroiditis. The SAT recurrence rate was 15.3%. There was no significant difference in the initial PSL dose between the non-recurrence and recurrence groups (27.5 mg vs 24.5 mg, P = 0.302). However, for the primary endpoint, significant differences were found between the two groups in time required for tapering PSL to 5 mg/day (non-recurrence: 44.3 ± 15.3 days, recurrence: 19.0 ± 11.9 days, P = 0.012). None of the clinical variables evaluated correlated significantly with SAT relapse. In conclusion, to prevent recurrence of SAT, consideration should be given to the period required for PSL tapering to 5 mg/day. \n亜急性甲状腺炎(SAT)に対するプレドニゾロン(PSL)治療中の再燃率は約10 - 20%である.しかしSAT の再発に至るまでの期間においてPSLの減量方法や再発に伴う因子に関する報告は無い.今回の研究ではPSLにて加療を行ったSATに対するPSLの減量方法と再燃との相関について検討することを目的とした.試験デザインは,カルテベースの後ろ向き研究で,対象は2004年1月から2013年7月にSATに対してPSLを投与した26名(男3名,女23名).主要評価項目は,再燃とPSL 5 mgに減量するまでに要した日数との関係,副次評価項目は再燃と年齢,clinical score( 活動性),free thyroxine,炎症反応,Thyroglobulin,総治療期間,総PSL量,Creepingの有無との関係とした.再燃率は15.3%であった.非再燃群と再燃群ではPSL初期投与量(27.5 mg vs 24.5 mg,P = 0.302) に有意差を認めない.しかし,主要評価項目:PSL 5 mgに減量するまでの日数(非再燃群:44.3 ± 15.3日 vs 再燃群:19.0 ± 11.9日,P = 0.012)に有意差を認めた.副次評価項目:その他の臨床的項目とSATの再燃との間に有意な相関は認めなかった.結論として,SATの再燃を起こさないためには,PSL減量日数に留意すべきであり,PSL 5 mgまでの減量には十分時間をかけるべきである. ", "subitem_description_type": "Abstract"}]}, "item_10001_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "産業医科大学(産業医科大学学会)"}]}, "item_10001_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "Journal of UOEH"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.uoeh-u.ac.jp/kouza/journal/intro_e.html", "subitem_relation_type_select": "URI"}}, {"subitem_relation_name": [{"subitem_relation_name_text": "産業医科大学雑誌"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.uoeh-u.ac.jp/kouza/journal/intro_j.html", "subitem_relation_type_select": "URI"}}]}, "item_10001_select_24": {"attribute_name": "記事区分", "attribute_value_mlt": [{"subitem_select_item": "Original"}]}, "item_10001_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "ISSN 0387-821X(PRINT), ISSN 2187-2864(ONLINE)", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "新生 , 忠司"}, {"creatorName": "アラオ, タダシ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "1852", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "岡田 , 洋右"}, {"creatorName": "オカダ, ヨウスケ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "1853", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "鳥本, 桂一"}, {"creatorName": "トリモト, ケイイチ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "1854", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "黒住 , 旭"}, {"creatorName": "クロズミ, アキラ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "1855", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "成澤 , 学"}, {"creatorName": "ナリサワ, マナブ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "1856", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "山本 , 直"}, {"creatorName": "ヤマモト, スナオ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "1857", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "田中, 良哉"}, {"creatorName": "タナカ, ヨシヤ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "1858", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Arao, Tadashi ", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1859", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Okada, Yosuke ", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1860", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Torimoto, Keiichi ", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1861", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kurozumi, Akira ", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1862", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Narisawa, Manabu ", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1863", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamamoto, Sunao ", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1864", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tanaka, Yoshiya ", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1865", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-07-27"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "01-新生 忠司, 他 先生.pdf", "filesize": [{"value": "1.3 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_11", "mimetype": "application/pdf", "size": 1300000.0, "url": {"label": "S00037201", "url": "https://uoeh-u.repo.nii.ac.jp/record/692/files/01-新生 忠司, 他 先生.pdf"}, "version_id": "4fda3dbd-9827-411f-b135-485ea9917a7c"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "亜急性甲状腺炎", "subitem_subject_scheme": "Other"}, {"subitem_subject": "プレドニゾロン", "subitem_subject_scheme": "Other"}, {"subitem_subject": "再燃率", "subitem_subject_scheme": "Other"}, {"subitem_subject": "投与方法", "subitem_subject_scheme": "Other"}, {"subitem_subject": "subacute thyroiditis", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prednisolone", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "the recurrence rate", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "dosing regimen", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "亜急性甲状腺炎に対するプレドニゾロン投与方法の検討", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "亜急性甲状腺炎に対するプレドニゾロン投与方法の検討"}, {"subitem_title": "Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis", "subitem_title_language": "en"}]}, "item_type_id": "10001", "owner": "4", "path": ["28"], "permalink_uri": "https://uoeh-u.repo.nii.ac.jp/records/692", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-08-03"}, "publish_date": "2020-08-03", "publish_status": "0", "recid": "692", "relation": {}, "relation_version_is_last": true, "title": ["亜急性甲状腺炎に対するプレドニゾロン投与方法の検討"], "weko_shared_id": -1}
亜急性甲状腺炎に対するプレドニゾロン投与方法の検討
https://uoeh-u.repo.nii.ac.jp/records/692
https://uoeh-u.repo.nii.ac.jp/records/69288fc4877-22d6-4e73-af65-0da4165ae8fe
名前 / ファイル | ライセンス | アクション |
---|---|---|
S00037201 (1.3 MB)
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-08-03 | |||||
タイトル | ||||||
タイトル | 亜急性甲状腺炎に対するプレドニゾロン投与方法の検討 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Prednisolone Dosing Regimen for Treatment of Subacute Thyroiditis | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 亜急性甲状腺炎 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | プレドニゾロン | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 再燃率 | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | 投与方法 | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | subacute thyroiditis | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | prednisolone | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | the recurrence rate | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | dosing regimen | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
記事区分 | ||||||
値 | Original | |||||
著者 |
新生 , 忠司
× 新生 , 忠司× 岡田 , 洋右× 鳥本, 桂一× 黒住 , 旭× 成澤 , 学× 山本 , 直× 田中, 良哉× Arao, Tadashi× Okada, Yosuke× Torimoto, Keiichi× Kurozumi, Akira× Narisawa, Manabu× Yamamoto, Sunao× Tanaka, Yoshiya |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The rate of recurrence of subacute thyroiditis (SAT) during prednisolone (PSL) therapy is approximately 10 to 20%. However, there is little or no information on the time period to relapse following administration of a tapered dose of PSL and the factors associated with such relapse. The aim of this study was to determine the correlation between SAT recurrence and PSL tapering regimen used in the treatment of SAT. This study was a medical record-based retrospective study and involved 26 patients (3 men, 23 women) who received PSL therapy for SAT. The primary endpoint was the association between recurrence and number of days required to taper daily PSL dose to 5 mg. The secondary endpoint was the relationship between recurrence and several variables including age, clinical score, free thyroxine, inflammatory reaction, thyroglobulin, total treatment time, total dose of PSL and presence or absence of creeping thyroiditis. The SAT recurrence rate was 15.3%. There was no significant difference in the initial PSL dose between the non-recurrence and recurrence groups (27.5 mg vs 24.5 mg, P = 0.302). However, for the primary endpoint, significant differences were found between the two groups in time required for tapering PSL to 5 mg/day (non-recurrence: 44.3 ± 15.3 days, recurrence: 19.0 ± 11.9 days, P = 0.012). None of the clinical variables evaluated correlated significantly with SAT relapse. In conclusion, to prevent recurrence of SAT, consideration should be given to the period required for PSL tapering to 5 mg/day. 亜急性甲状腺炎(SAT)に対するプレドニゾロン(PSL)治療中の再燃率は約10 - 20%である.しかしSAT の再発に至るまでの期間においてPSLの減量方法や再発に伴う因子に関する報告は無い.今回の研究ではPSLにて加療を行ったSATに対するPSLの減量方法と再燃との相関について検討することを目的とした.試験デザインは,カルテベースの後ろ向き研究で,対象は2004年1月から2013年7月にSATに対してPSLを投与した26名(男3名,女23名).主要評価項目は,再燃とPSL 5 mgに減量するまでに要した日数との関係,副次評価項目は再燃と年齢,clinical score( 活動性),free thyroxine,炎症反応,Thyroglobulin,総治療期間,総PSL量,Creepingの有無との関係とした.再燃率は15.3%であった.非再燃群と再燃群ではPSL初期投与量(27.5 mg vs 24.5 mg,P = 0.302) に有意差を認めない.しかし,主要評価項目:PSL 5 mgに減量するまでの日数(非再燃群:44.3 ± 15.3日 vs 再燃群:19.0 ± 11.9日,P = 0.012)に有意差を認めた.副次評価項目:その他の臨床的項目とSATの再燃との間に有意な相関は認めなかった.結論として,SATの再燃を起こさないためには,PSL減量日数に留意すべきであり,PSL 5 mgまでの減量には十分時間をかけるべきである. |
|||||
書誌情報 |
産業医科大学雑誌 en : Journal of UOEH 巻 37, 号 2, p. 103-110, 発行日 2015-06-03 |
|||||
出版者 | ||||||
出版者 | 産業医科大学(産業医科大学学会) | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | ISSN 0387-821X(PRINT), ISSN 2187-2864(ONLINE) | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.uoeh-u.ac.jp/kouza/journal/intro_e.html | |||||
関連名称 | Journal of UOEH | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.uoeh-u.ac.jp/kouza/journal/intro_j.html | |||||
関連名称 | 産業医科大学雑誌 |